Attovia Therapeutics, Inc. (NASDAQ: ATTO) reports Q2 2026 results, highlights ATTO-1310 Phase 1b progress and post-IPO cash runway
Attovia Therapeutics, Inc. (NASDAQ: ATTO) reported second-quarter 2026 financial results and provided a pipeline update, including preliminary Phase 1b signals for lead candidate ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, alongside an upsized IPO that the company said extends its expected cash runway into 2030.
Attovia Therapeutics News: Key Takeaways
- ATTO-1310 Phase 1b (chronic pruritus and high-itch atopic dermatitis) completed enrollment and dosing; complete Phase 1b data expected in Q4 2026.
- Attovia plans to initiate global Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin (CPUO) and high-itch atopic dermatitis in 1H 2027; CPUO protocol submitted to the FDA after incorporating agency feedback on design elements and endpoints.
- ATTO-2306 (IL-31/IL-13 bispecific) and ATTO-1091 (TL1A/IL-23p19/integrin a4β7 trispecific) are in IND-enabling activities, with Phase 1 initiation expected in 1H 2027.
- Company completed an upsized IPO with aggregate gross proceeds of about $332.4 million (net proceeds about $305.4 million) and said it expects cash runway into 2030.
- Q2 2026 collaboration revenue was $0.5 million (vs. $0 in Q2 2025); Q2 net loss was $20.7 million (vs. $14.4 million in Q2 2025).
- Cash, cash equivalents and marketable securities were $115.1 million as of June 30, 2026 (vs. $152.3 million as of Dec. 31, 2025).
Attovia Therapeutics Q2 2026: Key Financials
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Collaboration revenue | $0.5 million | $0.0 million | +$0.5 million |
| R&D expenses | $18.9 million | $13.6 million | +$5.3 million |
| G&A expenses | $3.3 million | $3.0 million | +$0.3 million |
| Net loss | ($20.7 million) | ($14.4 million) | -$6.3 million |
| Cash, cash equivalents and marketable securities | $115.1 million (June 30, 2026) | $152.3 million (Dec. 31, 2025) | -$37.2 million |
What happened?
The company’s lead program, ATTO-1310, is being developed for pruritic diseases and targets IL-31. Attovia said it completed enrollment and dosing in a double-blind, placebo-controlled Phase 1b study in patients with chronic pruritus and high-itch atopic dermatitis, and reported preliminary results consistent with clinical proof of concept. The company expects to report complete Phase 1b data in the fourth quarter of 2026.
Looking ahead, Attovia said it has submitted the protocol for a global Phase 2 study of ATTO-1310 in chronic pruritus of unknown origin to the FDA after incorporating feedback on study design and endpoints, with initiation planned in the first half of 2027. A separate global Phase 2 study in high-itch atopic dermatitis is also planned to start in the first half of 2027. In China, Attovia said it received IND clearance for a Phase 1b trial in cholestatic pruritus associated with primary biliary cholangitis or primary sclerosing cholangitis.
Beyond ATTO-1310, Attovia said ATTO-2306 and ATTO-1091 remain in IND-enabling activities, with Phase 1 initiation expected in the first half of 2027. The company also said it advanced ATTO-006 toward development candidate nomination by year-end 2026.
On the corporate side, Attovia completed an upsized IPO with aggregate gross proceeds of approximately $332.4 million and noted its shares now trade on the Nasdaq Global Market under the ticker symbol ATTO. The company also appointed John W. Smither to its board.
For the second quarter, Attovia reported $0.5 million in collaboration revenue related to research and development services under an EndPath RadioTherapeutics license agreement, compared with no collaboration revenue in the prior-year quarter. R&D expenses increased to $18.9 million, which the company attributed primarily to clinical, manufacturing and preclinical costs for ATTO-1310 and manufacturing and preclinical costs for ATTO-2306 and ATTO-1091. Net loss widened to $20.7 million.
Company Commentary
“Following the successful completion of our upsized IPO, Attovia enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creating milestones,” said Tao Fu, Founder and Chief Executive Officer of Attovia. “The preliminary clinical proof of concept for ATTO-1310 in chronic pruritus and high-itch AD provides important validation of both the program and our ATTOBODY platform. We are advancing ATTO-1310 toward two large Phase 2 studies while progressing ATTO-2306 and ATTO-1091 toward the clinic in the first half of 2027. With multiple internally discovered programs moving through development, we remain focused on disciplined execution and building Attovia into a sustainable, multi-product biotechnology company with the goal of shaping the future of immune-mediated diseases.”
Why this matters for investors
The update ties near-term clinical catalysts to Attovia’s capital position. The company reported preliminary Phase 1b signals for ATTO-1310 and set expectations for a full Phase 1b readout in Q4 2026, followed by planned Phase 2 starts in 1H 2027 in CPUO and high-itch atopic dermatitis.
Financially, Attovia’s cash position at June 30, 2026 reflected pre-IPO levels, but management said adding net proceeds of about $305.4 million from the August 2026 IPO is expected to fund operations into 2030. Investors will likely focus on execution toward the Phase 1b dataset, Phase 2 initiations, and progress of ATTO-2306 and ATTO-1091 through IND-enabling work ahead of expected Phase 1 starts in 1H 2027.